Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

VIEKIRA PAK (COPACKAGED)

DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR

Standard Dose
EQ 250MG BASE;12.5MG, 75MG, 50MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview VIEKIRA PAK (COPACKAGED) is listed in Drugs@FDA under application 206619 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR Form and strength TABLET;ORAL - EQ 250MG BASE;12.5MG, 75MG, 50MG Sponsor ABBVIE Submission history Latest submission status date: 2019-12-06 00:00:00.

Structured Monograph

Clinical summary

Approval overview VIEKIRA PAK (COPACKAGED) is listed in Drugs@FDA under application 206619 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR Form and strength TABLET;ORAL - EQ 250MG BASE;12.5MG, 75MG, 50MG Sponsor ABBVIE Submission history Latest submission status date: 2019-12-06 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
VIEKIRA PAK (COPACKAGED) (DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR) | Drug Monograph | MedicHelpline